Skip to main content

Advertisement

SpringerLink
Log in

Phase II Study of Troxacitabine (BCH-4556) in Patients with Advanced Non-Small-Cell Lung Cancer

  • Published:
Lung Aims and scope Submit manuscript

Abstract

Troxacitabine. a promising new L-nucleoside, inhibits DNA polymerase and leads to complete DNA chain termination. The National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) conducted a phase II study to assess the efficacy and toxicity of troxacitabine in untreated patients with advanced non-small-cell lung cancer (NSCLC). Previously untreated patients were eligible if they had inoperable stage IIIB or IV NSCLC, ECOG PS ≤ 2, adequate hematology and biochemistry, and at least one bidimensionally measurable lesion. Patients with prior malignancy or brain metastases were excluded. Troxacitabine (10 mg/m2) was administered intravenously over 30 minutes every 3 weeks. Between June 1999 and May 2000, 17 eligible patients received treatment. Patient characteristics included: median age 64 years; female 41%; stage IV (94%); PS 0 (12%), 1 (59%), and 2 (29 %), 3 or more disease sites (59%). In 17 patients, there were 8 stable disease, 9 disease progression, and no objective responses. Median duration of stable disease was 3.6 months (range = 2.0–7.1). A total of 56 cycles were administered (median = 3), and 88% of patients received 90% or more of the planned dose intensity. The majority (82%) of patients experienced skin rash. Hematologic and biochemical toxicities, grade 3/4 (%) were: granulocytopenia (41), anemia (12), thrombocytopenia (6), and hyperglycemia (6). Troxacitabine appears to have little activity in NSCLC in the dose and schedule tested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Cancer Society (2000) Cancer Facts and Figures 2000. Atlanta, GA

  2. American Society of Clinical Oncology (1999) American Society of Clinical Oncology, Clinical Practice Guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15:2996–3018

    Google Scholar 

  3. Anonymous (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group [see comments]. BMJ 311(7010):899–909

    Google Scholar 

  4. Attardo G, Kadhim S, Angers E, Bibeau L, Bowlin T (1997) Dose scheduling effects on the antitumor activity of BCH-4556 against human tumor xenografts in nude mice. In Proceedings of the American Association for Cancer Research Annual Meeting, San Diego, CA, Waverley Press, Volume 38, Abstract 670, p 38

  5. Belanger K, Moore M, Baker SD, Dionne J, Maclean M, Jolivet J, et al. (2002) Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days. J Clin Oncol 20(10):2567–2574; erratum, J Clin Oncol 20(15):3361

    Article  PubMed  Google Scholar 

  6. Biochem Pharma Inc. (1999) Troxacitabine (BHC-4556). Investigator’s Brochure. Laval, Quebec, Canada

  7. Bouffard DY, Laliberte J, Momparler RL (1993) Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 45(9):1857–1861

    Article  PubMed  Google Scholar 

  8. Bowlin T, Genne P, Kadhim S, Gourdeau H, Attardo G (1997) A novel cytidine nucleoside analog, BCH-4556, with potent activity against human anthracycline-resistant leukemia. In Proceedings of the American Association for Cancer Research Annual Meeting, San Diego, CA, Waverley Press, Volume 38, Abstract 668, p 38

  9. Canova A, Yee L, Baker S, Sarid R, Desforges C, Jolivet J, et al. (1999) A Phase I and Pharmacokinetic (PK) Study of β-L-Dioxalo-Cytidine (BCH-4556) Administered Weekly for Three Weeks Every 28 Days. In Proceedings of the Annual Meeting of the American Society of Clinical Oncologists, Atlanta, GA, ASCO, Alexandria, VA, Volume 18, Abstract 759

  10. Cortes-Funes H (2002) New treatment approaches for lung cancer and impact on survival. [review] [18 refs]. Semin Oncol 29(3 Suppl 8):26–29

    Article  Google Scholar 

  11. de Bono JS, Stephenson JJ, Baker SD, Hidalgo M, Patnaik A, Hammond LA, et al. (2002) Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 20(1):96–109

    Article  PubMed  Google Scholar 

  12. Gourdeau H, Bibeau L, Ouellet F, Custeau D, Bernier L, Bowlin T (2001) Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. Cancer Chemother Pharmacol 47(3):236–240

    Article  PubMed  Google Scholar 

  13. Grove KL, Guo X, Liu SH, Gao Z, Chu CK, Cheng YC (1995) Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res 55(14):3008–3011

    PubMed  Google Scholar 

  14. Kadhim SA, Bowlin TL, Waud WR, Angers EG, Bibeau L, DeMuys JM, Bednarski K, Cimpoia A, Attardo G (1997) Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res 57(21):4803–4810

    PubMed  Google Scholar 

  15. Rabbani SA, Harakidas P, Bowlin T, Attardo G (1998) Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo. Cancer Res 58(15):3461–3465

    PubMed  Google Scholar 

  16. Rivera MP (2001) Management of patients with advanced non-small-cell lung cancer [review] [37 refs]. Curr Opin Pulm Med 7(4):247–258

    Article  PubMed  Google Scholar 

  17. Sandier A, Ettinger DS (1999) Gemcitabine: single-agent and combination therapy in non-small cell lung cancer [see comments] [Review] [61 refs]. Oncologist 4(3):241–251

    PubMed  Google Scholar 

  18. Smith IE, O’Brien ME, Talbot DC, Nicolson MC, Mansi JL, Hckish TF, et al. (2001) Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19(5):1336–1343

    PubMed  Google Scholar 

  19. Weitman S, Marty J, Jolivet J, Locas C, Von Hoff DD (2000) The new dioxolane, (-)-2′-deoxy-3′-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts. Clin Cancer Res 6(4):1574–1578

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Cancer Institute of Canada (Clinical Trials Group), Kingston, Ontario, Canada

    S.F. Dent, A. Arnold, D.J. Stewart, S. Gertler, J. Ayoub, G. Batist, G. Goss, A. Nevile, D. Soulieres, L. Mclntosh & L. Seymour

  2. Shire Pharmaceutical Development Ltd, Montreal, Quebec, Canada

    J. Jolivet

  3. Ottawa Regional Cancer Center, 503 Smyth Rd., Ottawa, K1H 1C4, Ontario, Canada

    S.F. Dent

Authors
  1. S.F. Dent
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Arnold
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D.J. Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Gertler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Ayoub
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Batist
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Goss
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Nevile
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D. Soulieres
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J. Jolivet
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. L. Mclntosh
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. L. Seymour
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S.F. Dent.

Additional information

This work was supported by NCIC and BioChem Pharma Inc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dent, S., Arnold, A., Stewart, D. et al. Phase II Study of Troxacitabine (BCH-4556) in Patients with Advanced Non-Small-Cell Lung Cancer. Lung 183, 265–272 (2005). https://doi.org/10.1007/s00408-004-2539-7

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-004-2539-7

Keywords

Search

Navigation